Skip to main content

Emgality offers a specific 300 mg dose for patients with episodic cluster headache1

Cluster headache patient Frank

Redefine what’s possible for patients like Franka with Emgality 300 mg1

AGE: 40

CLUSTER HEADACHE FREQUENCY

  • 1 to 4 times per day during active periods that last 7 weeks, followed by periods (≥3 months) of remission

MEDICAL HISTORY

  • Diagnosed with episodic cluster headache 10 years ago

aHypothetical patient profile.

For the treatment of patients with episodic cluster headache,

Emgality 300 mg cut weekly cluster headache attacks in half or more for most patients1

Emgality 300 mg gives your patients a chance at ≥50% reduction in weekly cluster headache attack frequency1

  • 71.4% of patients on Emgality 300 mg (N=49) experienced a ≥50% response from baseline vs 52.6% of patients on placebo (N=57) (p=0.046)

Emgality 300 mg reduced the number of weekly cluster headache attacks by an average of 8.7 vs 5.2 with placebo over Weeks 1 to 3 (baseline: 17.8 vs 17.3) (p=0.036)1b

bLeast-square (LS) means are presented.

INDICATION

Emgality is indicated for the treatment of episodic cluster headache in adults.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Review Episodic Cluster Headache study design

SELECT IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

Explore the efficacy for Emgality or download savings cardsc for eligible patients

cGovernmental beneficiaries excluded.

References:

  1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
  2. Data on File. Lilly USA, LLC. DOF-GZ-US-0085.

IMPORTANT SAFETY INFORMATION

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 14SEP2022

INDICATIONS

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache